(Q35572535)

English

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 3 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Nicholas Van As

14

object named as

Nicolas Van As

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ananya Choudhury

object named as

Ananya Choudhury

10

0 references

21

object named as

Karim Fizazi

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Nadine Houédé

15

object named as

Nadine Houede

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

5

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Daniel P Petrylak

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Nicholas J Vogelzang

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Nikolay Budnik

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Pawel Jan Wiechno

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Kevin Doner

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Joaquim Bellmunt

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

John M Burke

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Maria Ochoa de Olza

9

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Juergen E Gschwend

11

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Evgeny Kopyltsov

12

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Aude Flechon

13

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Debora Barton

16

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Abderrahim Fandi

17

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ulf Jungnelius

18

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Shaoyi Li

19

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Ronald de Wit

20

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

3 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

417-425

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapies for metastatic castrate-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970025-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70025-2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35572535&oldid=2186354676"